Advertisements

Rheumocam

Quick links to important sections

Rheumocam

Selected form

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Rheumocam

Property Description
Active ingredient Meloxicam
Forms Tablets, Oral Suspension, Solution for Injection
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Symptomatic treatment of pain and inflammation
Origin Synthetic compound (Oxicam derivative)

What Type of Medicine is Rheumocam?

Rheumocam is a pharmaceutical preparation containing the active substance Meloxicam, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is typically available by prescription. This agent is a chemically defined, synthetic Oxicam derivative belonging to the enolic acid group. Pharmacological data indicates that Meloxicam exhibits a degree of preferential COX-2 inhibition. This characteristic mechanism provides a focused anti-inflammatory action by primarily targeting the enzyme responsible for generating pain signals. Meloxicam is recognized for its utility in managing pain and inflammation related to chronic conditions. The drug’s primary role is to act throughout the body to alleviate core symptoms of discomfort.


Rheumocam's Core Composition and Forms

The core of Rheumocam's identity is the presence of Meloxicam as the sole active ingredient, making it a single-component drug. The medicine is delivered via multiple administration routes, available for oral use as standard tablets and an oral suspension. It is also formulated as a sterile solution for injection for parenteral delivery. Both oral and injectable routes of administration are used to meet different patient needs. This highlights that the preparation is designed with multiple options to suit a need for either convenient or immediate action.


General Purpose and Benefit of Rheumocam

The general therapeutic purpose of Rheumocam is the symptomatic treatment of pain and the overall relief of physical signs of inflammation. The product's consistent anti-inflammatory effect and simultaneous analgesic effect are clinically recognized for their utility. A typical use scenario involves helping individuals manage the stiffness and pain associated with chronic musculoskeletal issues. By modulating the underlying biochemical process, the medicine helps to mitigate swelling and discomfort, supporting improved physical function.

Regulatory References

  1. Meloxicam: MedlinePlus Drug Information
Advertisements

What side effects are possible with Rheumocam ?

Possible Side Effects and Safety Information

The safety profile of Rheumocam is officially classified based on the frequency and system-organ-class of reported adverse reactions, according to regulatory standards.

Frequency-Classified Adverse Reactions

The following effects have been documented in regulatory sources:

  • Occasionally Reported (Uncommon/Rare): Loss of appetite (anorexia), vomiting, diarrhoea, faecal occult blood, lethargy/apathy, and renal failure.
  • Very Rarely Reported: Haemorrhagic diarrhoea, vomiting blood (haematemesis), gastrointestinal ulceration, elevated liver enzymes, and anaphylactoid (severe allergic) reactions.

Serious Adverse Reactions and Organ Systems

The primary system-organ classes involved are Gastrointestinal Disorders, Renal and Urinary Disorders, and Hepato-biliary Disorders. While most side effects are transient and resolve upon stopping treatment, gastrointestinal ulceration, haemorrhagic diarrhoea, renal failure, and anaphylactoid reactions have been noted as potentially serious or fatal in very rare cases.

Safety Restrictions and Contraindications

Rheumocam is subject to strict regulatory safety restrictions. It must not be administered in animals with pre-existing gastrointestinal disorders (such as irritation or haemorrhage), impaired hepatic, cardiac, or renal function, or known haemorrhagic disorders. It is also contraindicated for use in pregnant or lactating animals. Safety has not been established for use in dogs and cats below specific age and weight thresholds (e.g., typically less than 6 weeks of age). Use must be avoided in any dehydrated, hypovolaemic, or hypotensive animal due to increased risk of renal toxicity, and it must not be combined with other NSAIDs or glucocorticosteroids.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Rheumocam (Meloxicam) by identifying both mild and life-threatening manifestations, necessitating a strictly procedural management approach.

Documented Overdose Manifestations

Overdose presentations are initially defined by generally reversible symptoms, which may include lethargy, drowsiness, nausea, vomiting, and epigastric pain. Severe poisoning, however, is associated with critical systemic effects.

Severe Outcomes and Organ Systems

Life-threatening outcomes documented in the labeling include severe effects on the cardiovascular, renal, and central nervous systems, such as acute renal failure, hepatic dysfunction, respiratory depression, coma, convulsions, cardiac arrest, and gastrointestinal bleeding. Anaphylactoid reactions may also occur following an overdose.

Emergency Action and Management

Immediate medical attention must be sought for any severe symptom or suspected anaphylactoid reaction. Regulatory guidance states that patients must be managed with symptomatic and supportive care as no specific antidote is known. Documented supportive measures may include the use of gastric lavage or activated charcoal for rapid drug clearance. Procedures such as hemodialysis are documented as ineffective.

Advertisements

Therapeutic Uses of Rheumocam

What Rheumocam Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed.

Rheumocam is commonly used across conditions presenting with acute episodes, such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Idiopathic Arthritis (JIA). It is relevant in contexts involving heightened systemic burden, offering symptomatic relief that contributes to easing the overall symptom load.

It helps address symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort and functional strain. The medication is applied during phases of increased distress or discomfort, relevant when short-term symptomatic assistance is needed.

“This medicine is commonly used to support general well-being during symptomatic phases and assists with maintaining functional stability.”

Provides support that helps ease the overall symptom burden, supporting patients during difficult episodes by easing distress.


Quick Fact: Easing of Physical Discomfort and Functional Strain

Regulatory References

  1. Meloxicam: MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use

Rheumocam (Meloxicam) eligibility is strictly defined by regulatory standards to exclude patients with specific conditions and hypersensitivity risks.

Absolute Contraindications

The medicine must not be used by patients with a known hypersensitivity to meloxicam or a history of allergic-type reactions (such as asthma or urticaria) after taking aspirin or other NSAIDs. Use is also strictly contraindicated in the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery.

Absolute exclusion applies to patients with: active or recent gastrointestinal bleeding/ulceration, severe heart failure, severe liver function impairment, and non-dialysed severe renal failure.

Age and Life Stage Rules

The medicine is approved for Adults. Pediatric use is approved only for Juvenile Idiopathic Arthritis (JIA) in patients 2 years of age and older (US labeling), with tablet formulations typically restricted to those weighing 60 kg or more. In the third trimester of pregnancy, use is formally contraindicated due to the risk of fetal harm; use is restricted between 20 and 30 weeks gestation. Use is generally not recommended for nursing mothers.

Conditional Use and Restrictions

Older adults are classified as a higher-risk population, requiring increased vigilance for gastrointestinal and renal health. Patients with pre-existing risk factors, such as uncontrolled hypertension or established ischemic disease, must be treated only after careful consideration of their overall profile, as stipulated in official regulatory documents.

Advertisements

What should I know about interactions with other medicines?

Rheumocam Interactions with other medicines and products

This section outlines the officially documented interaction profile of Rheumocam (Meloxicam) based strictly on authoritative government regulatory information.

Interaction Constraints and Prohibitions

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including other COX-2 selective inhibitors and analgesic doses of Aspirin, is generally not recommended due to a heightened risk of gastrointestinal adverse effects. Regulatory guidance also states that Meloxicam is contraindicated for the management of peri-operative pain related to Coronary Artery Bypass Graft (CABG) surgery.

Pharmacodynamic and Exposure Interactions

Meloxicam, a non-steroidal anti-inflammatory drug, interacts with several product classes by either increasing a risk or modifying concentration levels:

  • Risk of Bleeding: Increased risk of haemorrhage is documented when Rheumocam is co-administered with Anticoagulants (e.g., Warfarin, Heparin), Antiplatelet agents, Corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs).
  • Antihypertensive Effect Diminished: Meloxicam may reduce the therapeutic effect of certain blood pressure medications, including Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARBs).
  • Partner Drug Exposure Elevated: Meloxicam can increase the plasma concentrations of drugs like Lithium and Methotrexate, necessitating monitoring.
  • Accelerated Clearance: The bile acid sequestrant Cholestyramine accelerates the clearance of Meloxicam from the body, leading to reduced plasma levels.

Population Note: Caution is specifically noted for the elderly and those with pre-existing volume depletion or renal impairment, where co-use with ACE Inhibitors or ARBs may increase the risk of acute renal function deterioration.

Advertisements

Mechanism of Action

How Rheumocam Works

Rheumocam's action is defined by the pharmacodynamics of its active component, Meloxicam, focusing on the modulation of the eicosanoid cascade through enzyme inhibition. The primary molecular target is the Cyclooxygenase-2 (COX-2) enzyme, which is preferentially inhibited over the COX-1 isoform. This interaction blocks the catalytic conversion of arachidonic acid into pro-inflammatory prostaglandins at the site of pathology.

This molecular blockade initiates a critical cascade. Reduced prostaglandin synthesis influences both peripheral and central physiological pathways. Peripherally, it modulates nociceptive pathway activity by decreasing the responsiveness of peripheral nociceptors and results in a decrease in local vascular permeability, which is the physiological basis of the anti-exudative effect. Centrally, the mechanism extends to the hypothalamus, suppressing PGE2 synthesis, thereby influencing the mechanism that mediates the elevation of the body's thermal set point. The combined result is a defined modulation of inflammatory, nociceptive, and thermoregulatory signaling.

Advertisements

Dosage and Administration Information

Official Administration Routes and Dosing

Rheumocam (meloxicam) is administered via the oral route, available as tablets or oral suspension, and by intravenous (IV) injection for short-term use. Dosing is based on established clinical parameters.


Administration Schedule

The medicine is taken as a single dose once daily across all approved oral and intravenous forms.

Form and Route Adult Dosing Regimen (Once Daily) Maximum Daily Dose
Oral Tablets (7.5 mg, 15 mg) Starting dose of 7.5 mg, may be increased to 15 mg. 15 mg
Intravenous Injection (IV) 30 mg IV bolus over 15 seconds. 30 mg

Contextual Use Instructions

Administration instructions for the oral form vary. Tablets may be taken without regard to the timing of meals, or in some instances, taken with water or another liquid during a meal.

A core therapeutic principle for all use is to apply the lowest effective dose for the shortest duration consistent with treatment goals. The IV form is specifically limited to short-term use, such as up to two initial doses for acute pain management.

Population-Specific Constraints

Specific dosage limits apply to certain patient groups. For adults undergoing hemodialysis, the maximum daily oral dose of meloxicam tablets is restricted to 7.5 mg. The use of the medicine is generally not recommended in patients with severe renal impairment who are not on dialysis. For pediatric patients (aged ge 2 years, weighing ge 60 kg) approved for use, the oral dose is 7.5 mg once daily.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Rheumocam


Evidence for Use in Osteoarthritis (OA)

The research base for Rheumocam in the context of Osteoarthritis (OA) includes Randomized Controlled Trials (RCTs). These studies were designed to evaluate patterns observed in adult patients with OA. Researchers conducted trials against both inactive comparisons (placebo) and established, active treatments. The studies focused on outcomes related to physical discomfort, measuring changes in reported pain levels and scores that reflect daily functioning or activity level, such as the WOMAC scale. Studies spanning around 12 weeks describe patterns observed in the measured symptomatic outcomes. The research shows that while short-term symptom patterns were monitored, long-term outcomes for patients with OA are not fully established. Comparative evidence is still emerging regarding comparisons to all newer non-steroidal anti-inflammatory drugs (NSAIDs) in specific head-to-head trial designs.


Evidence for Use in Rheumatoid Arthritis (RA)

Research examined Rheumocam in the context of conditions characterized by fluctuating or episodic manifestations in adult patients with Rheumatoid Arthritis (RA). Studies explored symptomatic changes over defined time intervals, utilizing multi-center, controlled trials. The research monitored outcomes linked to phases of heightened symptom activity using standardized clinical endpoints, such as the ACR 20 response criteria, which track changes in the number of tender and swollen joints. Controlled trials of 3-week to 6-month durations report measurements of the changes in the core signs and symptoms of RA. The observed relationship between dose levels and symptomatic patterns remains an area of research; studies monitored different dosages, but findings indicated that higher dosages did not show consistently different patterns in short-term outcomes.


Evidence for Use in Juvenile Idiopathic Arthritis (JIA)

Research exploring Meloxicam in the context of Juvenile Idiopathic Arthritis (JIA) examined pediatric patients (children aged two years and older). These studies were typically active-controlled clinical trials. The research monitored outcomes reflecting daily functioning or activity level using the ACR Pedi 30 response criteria. Studies tracking patient responses over defined time intervals ranged up to 12 months. A key limitation is that the overall evidence base for JIA is smaller than for adult conditions, and research is primarily based on a limited number of dedicated randomized controlled trials.

Key Studies & References

  1. Meloxicam: MedlinePlus Drug Information
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Rheumocam (FAQ)


Q: How quickly does Rheumocam start to work after taking it?

According to official product information, after an oral dose of Rheumocam, the active substance, meloxicam, reaches its maximum concentration in the blood within approximately four to six hours. This timeframe represents when the active substance, meloxicam, generally reaches its maximum concentration in the blood.


Q: Do you have to take Rheumocam with food, or can it be taken on an empty stomach?

Official guidance states that Rheumocam oral tablets may be taken with or without regard to food. However, some regulatory labels also note that taking the dose with water or another liquid during a meal is an option. Regulatory documents indicate that patients who have concerns about stomach upset may find taking the dose with food to be more tolerable.


Q: How long does Rheumocam stay in your system after you stop taking it?

The time it takes for the medicine to be eliminated is described by its elimination half-life, which is typically between 15 and 20 hours. This means it takes this long for half of the drug to be cleared from your bloodstream. The medicine and its inactive components are removed from the body primarily through the kidneys and feces.


Q: Does Rheumocam affect liver enzymes that show up on blood tests?

Yes, regulatory documents indicate that the use of meloxicam has been associated with elevated liver enzymes, such as ALT and AST, as an adverse reaction. These changes can be detected during blood tests. The potential for elevated liver enzymes is why monitoring liver function may be part of the overall safety assessment during treatment.


Q: Are there different strengths of Rheumocam available?

Yes, Rheumocam (meloxicam) is available in several forms and strengths. The oral forms include tablets and an oral suspension. An injectable solution is also available, which is typically reserved for short-term use in managing acute pain.


Q: Does Rheumocam cause weight gain, or is that a myth?

Meloxicam, like other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), has been associated with fluid retention and edema (swelling). This buildup of fluid can sometimes result in an increase in weight. Unexplained weight changes or swelling are effects that should be discussed with a healthcare professional.


Q: Can Rheumocam be taken long-term, or is it only for short periods?

The general principle for using this medicine is to apply the lowest effective dose for the shortest duration that aligns with your treatment goals. It is important to note that chronic use may carry increased risks of serious side effects, particularly affecting the gastrointestinal tract and cardiovascular system, as stated in regulatory warnings.


Q: What happens if I accidentally miss a dose of Rheumocam?

Official patient information advises that if a dose is missed, it should be taken as soon as possible. However, if it is almost time for your next scheduled dose, you should skip the missed dose entirely and simply continue with your regular schedule. Official guidance warns against taking a double dose to compensate for a missed dose.


Q: Is it normal to feel a bit dizzy or tired after starting Rheumocam?

Yes, regulatory documents list adverse reactions that have been reported, which include feelings of dizziness and general fatigue or tiredness. Any concerning or persistent effects should be discussed with a healthcare provider.


Q: What are the most common side effects people report when using Rheumocam?

Clinical trials indicate that the most commonly reported adverse reactions, occurring in 2% or more of patients, include abdominal pain, diarrhea, indigestion (dyspepsia), headache, and nausea. These are generally the effects most frequently observed when starting the medication.


Q: Can Rheumocam cause changes in sleep patterns?

Yes, adverse reactions that affect the psychiatric and nervous system have been reported. These can include changes in sleep, such as insomnia (difficulty sleeping) and episodes of abnormal dreaming.


Q: Can Rheumocam cause skin rashes or increased sensitivity to the sun?

Official information indicates that skin-related adverse reactions have been reported, including rash and pruritus (itching). Additionally, photosensitivity reaction—an increased sensitivity to sunlight—is a reported side effect.


Q: Is there a possibility of becoming dependent on Rheumocam?

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not classified as a controlled substance. Therefore, it does not carry the same risk of physical dependence that is associated with opioid pain medications.


Q: Can Rheumocam be used safely by people with kidney issues?

Official information states that use of Rheumocam is not recommended for individuals with moderate to severe renal insufficiency. It is strictly contraindicated (must not be used) in patients with severe kidney failure who are not on dialysis. Dosage limitations are also required for patients undergoing hemodialysis.


Q: What are some of the long-term effects of taking Rheumocam regularly?

Regulatory warnings indicate that long-term use is associated with several serious risks. These include increased risk of cardiovascular events, such as heart attack or stroke, and increased risk of serious gastrointestinal issues, including bleeding and ulceration.


Q: Is it normal to feel a change in appetite while on Rheumocam?

Yes, changes in appetite have been listed as reported adverse reactions. Specifically, some patients have experienced loss of appetite (anorexia), and less commonly, some may notice an increase in appetite.


Q: Does Rheumocam have an effect on mood or anxiety?

Adverse reactions related to the psychiatric system have been reported in association with meloxicam. These include changes such as anxiety, confusion, depression, mood elevation, and nervousness.


Q: Can Rheumocam cause temporary changes in vision?

Yes, the product information indicates that adverse effects related to the special senses have been reported. These include abnormal vision and an eye condition called conjunctivitis.


Q: Is it safe to drive or operate machinery while taking Rheumocam?

Meloxicam has the potential to cause side effects such as dizziness, somnolence (sleepiness), and vision disturbances. Official guidance advises that patients experiencing these effects should avoid activities like driving or operating machinery until the symptoms have completely resolved.


Q: Why is Rheumocam prescribed for both chronic and acute issues?

Rheumocam is officially approved for managing the chronic symptoms of conditions like Osteoarthritis and Rheumatoid Arthritis. Separately, the injectable (IV) formulation is specifically authorized for short-term use, which allows it to be used in managing acute pain situations.

Advertisements

How should Rheumocam be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents define the storage and disposal of Rheumocam based on the official product labeling. The sealed, unopened product does not require any special storage conditions.

Key Stability and Protection Rules

Condition Requirement
In-Use Stability The oral suspension must be discarded after a defined period from first opening (e.g., 6 months for some formulations; consult label).
Handling Shake the oral suspension well before use.
Child Safety Keep out of the reach and sight of children.
Disposal Any unused or expired product must be disposed of in accordance with local regulatory requirements, and should not be discarded into wastewater or household trash.

These constraints ensure the product maintains its stability and minimize environmental exposure, as mandated by health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rheumocam  found in:

A-Z Index: